Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Genetics in medicine : official journal of the American College of Medical Genetics(2023)
摘要
These findings confirm the long-term efficacy of eliglustat on skeletal complications of Gaucher disease in treatment-naïve and ERT-switch patients.
更多查看译文
关键词
Acid β-glucosidase deficiency,Eliglustat,Gaucher disease type 1,Skeletal manifestations,Substrate reduction therapy
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要